Protalix BioTherapeutics (PLX) Accounts Payables (2010 - 2026)
Protalix BioTherapeutics' quarterly Accounts Payables came in at $4.3 million in Q1 2026, up 3.98% year-on-year from $4.1 million in Q1 2025, and down 18.52% quarter-over-quarter from $5.3 million in Q4 2025.
Protalix BioTherapeutics has reported Accounts Payables for 17 years, with the latest figure at $4.3 million in Q1 2026.
- For the quarter ending Q1 2026, Accounts Payables rose 3.98% year-over-year to $4.3 million; the trailing twelve-month figure through Mar 2026 stood at $4.3 million (up 3.98% YoY), and the FY2025 full-year result was $5.3 million, up 16.02% from the prior year.
- Accounts Payables for Q1 2026 stood at $4.3 million, down from $5.3 million in the prior quarter.
- The five-year high for Accounts Payables was $19.6 million in Q3 2024, with the low at $4.1 million in Q2 2024.
- Average Accounts Payables over 5 years is $10.2 million, with a median of $6.7 million recorded in 2025.
- Year-over-year, Accounts Payables surged 126.07% in 2022 and plunged 78.09% in 2024.
- Tracing PLX's Accounts Payables over 5 years: stood at $5.9 million in 2022, then dropped by 26.31% to $4.3 million in 2023, then climbed by 4.93% to $4.5 million in 2024, then increased by 16.02% to $5.3 million in 2025, then slipped by 18.52% to $4.3 million in 2026.
- The last three Accounts Payables figures came in at $4.3 million (Q1 2026), $5.3 million (Q4 2025), and $5.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 4.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.29 Mn |
| Dec 31, 2025 | 5.26 Mn |
| Sep 30, 2025 | 5.38 Mn |
| Jun 30, 2025 | 6.69 Mn |
| Mar 31, 2025 | 4.12 Mn |
| Dec 31, 2024 | 4.53 Mn |
| Sep 30, 2024 | 19.58 Mn |
| Jun 30, 2024 | 4.06 Mn |
| Mar 31, 2024 | 18.77 Mn |
| Dec 31, 2023 | 4.32 Mn |
| Sep 30, 2023 | 18.74 Mn |
| Jun 30, 2023 | 18.55 Mn |
| Mar 31, 2023 | 13.47 Mn |
| Dec 31, 2022 | 5.86 Mn |
| Sep 30, 2022 | 12.87 Mn |
| Jun 30, 2022 | 12.66 Mn |
| Mar 31, 2022 | 14.41 Mn |
| Dec 31, 2021 | 16.43 Mn |
| Sep 30, 2021 | 14.69 Mn |
| Jun 30, 2021 | 14.42 Mn |
| Mar 31, 2021 | 6.38 Mn |
| Dec 31, 2020 | 13.93 Mn |
| Sep 30, 2020 | 8.35 Mn |
| Jun 30, 2020 | 11.91 Mn |
| Mar 31, 2020 | 9.43 Mn |
| Dec 31, 2019 | 6.50 Mn |
| Sep 30, 2019 | 7.76 Mn |
| Jun 30, 2019 | 10.50 Mn |
| Mar 31, 2019 | 10.48 Mn |
| Dec 31, 2018 | 5.21 Mn |
| Sep 30, 2018 | 4.39 Mn |
| Jun 30, 2018 | 9.07 Mn |
| Mar 31, 2018 | 10.70 Mn |
| Dec 31, 2017 | 7.52 Mn |
| Sep 30, 2017 | 8.69 Mn |
| Jun 30, 2017 | 7.85 Mn |
| Mar 31, 2017 | 12.37 Mn |
| Dec 31, 2016 | 7.50 Mn |
| Sep 30, 2016 | 3.99 Mn |
| Jun 30, 2016 | 3.82 Mn |
| Mar 31, 2016 | 4.76 Mn |
| Dec 31, 2015 | 3.63 Mn |
| Dec 31, 2014 | 6.80 Mn |
| Mar 31, 2014 | 14.53 Mn |
| Dec 31, 2013 | 5.25 Mn |
| Sep 30, 2013 | 12.40 Mn |
| Jun 30, 2013 | 3.94 Mn |
| Mar 31, 2013 | 12.06 Mn |
| Dec 31, 2012 | 11.05 Mn |
| Sep 30, 2012 | 4.43 Mn |
| Jun 30, 2012 | 11.96 Mn |
| Mar 31, 2012 | 4.57 Mn |
| Dec 31, 2011 | 5.03 Mn |
| Sep 30, 2011 | 4.96 Mn |
| Jun 30, 2011 | 5.85 Mn |
| Dec 31, 2010 | 8.07 Mn |